Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 3;5(1):oeae106.
doi: 10.1093/ehjopen/oeae106. eCollection 2025 Jan.

Characterization of LTBP2 mutation causing mitral valve prolapse

Affiliations

Characterization of LTBP2 mutation causing mitral valve prolapse

Shoshi Shpitzen et al. Eur Heart J Open. .

Abstract

Aims: Mitral valve prolapse (MVP) is a common valvular disorder associated with significant morbidity and mortality, with a strong genetic basis. This study aimed to identify a mutation in a family with MVP and to characterize the valve phenotype in LTBP2 knockout (KO) mice.

Methods and results: Exome sequencing and segregation analysis were performed on a large family with MVP. Two mouse strains were generated: a complete KO of the LTBP2 gene and a knockin (KI) of the human mutation. At 6 months, phenotyping was conducted using echocardiography, histology, eye optical coherence tomography, and quantitative polymerase chain reaction analysis for TGF-β signalling targets (periostin/POSTN, RUNX2, and CTGF) in valve tissues. LTBP2 rs117800773 V1506M mutation exhibited segregation with MVP. LTBP2 KO mice had a higher incidence of myxomatous changes by histology (7 of 9 of KO vs. 0 of 7 control animals, P = 0.00186) and echocardiography (7 of 9 vs. 0 of 8, P = 0.0011). LTBP2 KI mice for the human mutation showed a significantly elevated myxomatous histological phenotype (8 of 8 vs. 0 of 9, P = 0.00004) as well as by echocardiography (6 of 8 vs. 0 of 9, P = 0.00123). Knockout mice demonstrated an increase in the depth of the anterior chamber as well as reduced visual acuity. LTBP2 KO mice demonstrated overexpression of both TGF-β signalling targets RUNX2 and periostin (P = 0.0144 and P = 0.001826, respectively).

Conclusion: We report a KO mouse strain with an LTBP2 mutation, demonstrating a valve phenotype, alongside a family with a novel mutation linked to MVP.

Keywords: LTBP2; Mitral valve prolapse; Myxomatous valve.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
(A) Pedigree demonstrating LTBP2 V1506M mutation. Segregation with mitral valve prolapse in the pedigree. Dark shapes are mitral valve prolapse, and empty shapes are normal phenotype. A question mark denotes either equivocal phenotype or that an echocardiogram was not available. LTBP2 genotype is at the bottom: CC is the wild-type allele and CT heterozygote for the V1506M mutation. The left top number is a serial number for the individual in the family. The right top number when available is the age of phenotyping. (B) The sequence variation with a blue arrow pointing to the mutation. (C) A demonstrative parasternal long axis with and without colour Doppler of individual 004, demonstrating mitral valve prolapse and significant regurgitation.
Figure 2
Figure 2
Valve phenotype of LTBP2 deficiency. Echocardiograms of 6-month-old knockout (A) and wild type (B). The line delineates annular line. The arrow is pointing to the posterior leaflet. Mitral valve LTBP2 immunofluorescence in a knockout mouse (C) and wild type (D). Notice the Cy5 colouring (red) of the wild-type valve that is lacking in the knockout. (E–G) Movat pentachrome straining of knockout, knockin, and wild-type mice, respectively. Black arrows are pointing at the leaflets. Notice the marked thickening and fibrosis with myxomatous changes of the valve leaflets in the knockout (black arrows) (E) and the widespread blue staining of mucinous substance (arrow) (F). The leaflets of the wild-type mice are thin and are not stained blue (G).
Figure 3
Figure 3
Ocular structure and visual function. Ocular structure and visual function in 12–14-month-old LTBP2 knockout mice. Left bars represent wild-type mice, and right bars represent LTBP2 knockout mice. Results are presented as mean ± SEM. Number of animals in each group is written within the corresponding bar. *P < 0.05; **P < 0.0001. (A) Comparison between wild-type and LTBP2 knockout mouse eyes revealed a significant increase in the anterior chamber depth in mutant mice as measured using in vivo optical coherence tomography imaging of the anterior segment. Representative images from 12-month-old mice are shown to the right of the bar graph. Anterior chamber depth reflects the distance between the corneal endothelium and the anterior capsule of the lens and is marked by red lines. Scale bars, 240 μm. (B) Knockout of the LTBP2 gene also led to significant enlargement of the iridocorneal angle. Representative images of iridocorneal angle (marked by yellow dotted lines) in 12-month wild-type and LTBP2 knockout mice. (C) From 12 months of age and on, LTBP2 knockout mice exhibited very poor dilation of the pupils in response to topical application of mydriatic drops. Measurements revealed a statistically significant reduction in pharmacologically dilated pupil diameter in mutant mice compared with age-matched wild-type mice. Representative images of eyes of 12-month-old mice captured in infra-red mode are presented to the right of the graph. (D) Representative images of eye sections from 12-month-old mice, taken through the central cornea and optic nerve and stained with haematoxylin and eosin, align with our in vivo optical coherence tomography findings. Mutant eyes show a deeper anterior chamber caused by posterior subluxation of the lens accompanied by an increased iridocorneal angle, reduced depth of the vitreous cavity, and a narrow pupil. Scale bar, 500 μm. (E) Visual acuity as measured using the optomotor response revealed a significant reduction in LTBP2 knockout mice compared with wild-type mice.

References

    1. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999;341:1–7. - PubMed
    1. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2019;32:1–64. - PubMed
    1. Levine Robert A, Durst R. Mitral valve prolapse: a deeper look. JACC Cardiovasc Imaging 2008;1:304–306. - PMC - PubMed
    1. Levine RA, Hagége AA, Judge DP, Padala M, Dal-Bianco JP, Aikawa E, Beaudoin J, Bischoff J, Bouatia-Naji N, Bruneval P, Butcher JT, Carpentier A, Chaput M, Chester AH, Clusel C, Delling FN, Dietz HC, Dina C, Durst R, Fernandez-Friera L, Handschumacher MD, Jensen MO, Jeunemaitre XP, Le Marec H, Le Tourneau T, Markwald RR, Mérot J, Messas E, Milan DP, Neri T, Norris RA, Peal D, Perrocheau M, Probst V, Pucéat M, Rosenthal N, Solis J, Schott JJ, Schwammenthal E, Slaugenhaupt SA, Song JK, Yacoub MH; Leducq Mitral Transatlantic Network . Mitral valve disease—morphology and mechanisms. Nat Rev Cardiol 2015;12:689–710. - PMC - PubMed
    1. Guicciardi NA, De Bonis M, Di Resta C, Ascione G, Alfieri O, Maisano F, Vergara P. Genetic background of mitral valve prolapse. Rev Cardiovasc Med 2022;23:96. - PubMed